Metabolomics Study Revealing Purines as Potential Diagnostic Biomarkers of Acute Respiratory Distress Syndrome in Patients with CommunityAcquired Pneumonia

• Published in: Journal of proteome research 2023-08, Vol.22 (8), p.2558-2569
• Main Authors: Xiong, Fen, Jiang, Kaiyuan, Chen, Jianuo, Yan, Yongqin, Zhou, Yiyang, Chen, Zihao, Zheng, Hong, Li, Yuping, Gao, Hongchang
• Format: Article
• Language: English
• Subjects: Biomarkers; Community-Acquired Infections - complications; Community-Acquired Infections - diagnosis; Fatty Acids; Humans; Metabolomics; Pneumonia - diagnosis; Purines; Respiratory Distress Syndrome - diagnosis; Respiratory Distress Syndrome - etiology; Respiratory Distress Syndrome - metabolism
• ISSN: 1535-3893; 1535-3907
• DOI: 10.1021/acs.jproteome.2c00788

Community-acquired pneumonia (CAP) is a significant threat to human health and the leading cause of acute respiratory distress syndrome (ARDS). We aimed to reveal the metabolic profiling whether can be used for assessing CAP with or without ARDS (nARDS) and therapeutic effects on CAP patients after treatment. Urine samples were collected at the onset and recovery periods, and metabolomics was employed to identify robust biomarkers. 19 metabolites were significantly changed in the ARDS relative to nARDS, mainly involving purines and fatty acids. After treatment, 7 metabolites in the nARDS and 14 in the ARDS were found to be significantly dysregulated, including fatty acids and amino acids. In the validation cohort, we observed that the biomarker panel consisted of N 2,N 2-dimethylguanosine, 1-methyladenosine, 3-methylguanine, 1-methyladenosine, and uric acid exhibited better AUCs of 0.900 than pneumonia severity index and acute physiology and chronic health evaluation II (APACHE II) scores between the ARDS and nARDS. Combining L-phenylalanine, phytosphingosine, and N-acetylaspartylglutamate as biomarkers for discriminating the nARDS and ARDS patients after treatment exhibited good AUCs of 0.811 and 0.821, respectively. The metabolic pathway and defined biomarkers may serve as crucial indicators for predicting the development of ARDS in CAP patients and for assessing therapeutic effects.